Skip to main content

Table 1 Chronic myeloid leukemia case description and survival analysis

From: The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

CML Case Characteristics

DIAGNOSIS PRE-TKI

(before February 1, 2002)

DIAGNOSIS Post-TKI

(after February 1, 2002)

dead on August 1, 2002

(Pre-TKI cases)

alive on August 1, 2002

(Prevalent cases)

(Incident cases)

SEX

N

%

N

%

N

%

 M

48

64.0

42

57.5

117

56.0

 F

27

36.0

31

42.4

92

44.0

AGE AT DIAGNOSIS

  < 65 yrs

17

22.7

40

54.8

117

56.0

 65–74 yrs

23

30.7

22

30.1

46

22.0

  > 74 yrs

35

46.7

11

15.1

46

22.0

RESIDENCY

 non-mountainous area

64

85.3

65

89.0

193

92.3

 mountainous area

11

14.7

8

11.0

16

7.7

TOTAL

75

100

73

100

209

100

SURVIVAL

Diagnosis before February 1, 2002

Diagnosis after February 1, 2002

Relative Survival

% (95% CI)

Disease-specific Survival

% (95% CI)

Relative Survival

% (95% CI)

Disease-specific Survival

% (95% CI)

 1 year

81.43%

(73.55–87.47)

83.36%

(76.21–88.53)

90.54%

(85.31–94.22)

91.28%

(86.52–94.42)

 3 years

56.55%

(47.34–65.06)

60.38%

(51.69–68.00)

80.95%

(74.26–86.40)

84.52%

(78.70–88.86)

 5 years

40.82%

(31.96–49.75)

47.26%

(38.49–55.53)

77.01%

(69.65–83.25)

80.85%

(74.49–85.78)

 10 years

34.50%

(25.76–43.76)

38.41%

(29.90–46.85)

70.85%

(61.55–79.08)

76.97%

(69.52–82.82)

5-yr SURVIVAL by AGE AT DIAGNOSIS

Diagnosis before February 1, 2002

Diagnosis after February 1, 2002

Relative Survival

% (95% CI)

Disease-specific Survival % (95% CI)

Relative Survival

% (95% CI)

Disease-specific Survival % (95% CI)

  < 65 yrs

66.34%

(51.84–77.60)

69.08%

(55.03–79.52)

92.49%

(85.31–96.59)

94.63%

(88.41–97.55)

 65–74 yrs

39.31%

(23.83–55.31)

46.77%

(30.83–61.22)

67.59%

(50.58–81.06)

69.01%

(52.50–80.78)

  > 74 yrs

3.49%

(0.28–15.97)

8.05%

(0.81–26.72)

40.27%

(22.01–60.78)

51.21%

(32.44–67.17)

  1. Characteristics of cases of chronic myeloid leukemia diagnosed from 1996 to 2012 in the provinces of Modena and Reggio Emilia, Italy, classified by date of diagnosis (before or after February 1, 2002) and status (dead or alive) on August 1, 2002. February 1, 2002 was the date of the first purchase of imatinib by the Local Health Authorities of Modena and Reggio Emilia and August 1, 2002 was the date of the plausible full implementation of the new therapy for all the prevalent cases, according to current guidelines. Disease-specific survival was assessed for all cases with follow up to December 31, 2015. Five-year disease-specific survival stratified by age class at diagnosis was also calculated